header logo image


Page 1,024«..1020..1,0231,0241,0251,026..1,0301,040..»

Meet Malikaa Marathe, the girl who went from having partial eyesight to becoming first in tennis – YourStory.com

April 24th, 2017 12:44 pm

Malikaa Marathe, who was partially blind for four years when she was a kid, is now ranked first in the All India Tennis Association (AITA) rankings for girls.

Growing up, Malikaa was like any other child her age, until she was affected by amblyopia or lazy eye. This is a condition where one has vision problems as a result of the brain and eye not working well together. She was affected by amblyopia in her right eye and to strengthen that eye, she had to wear a patch on her left eye according to The Frustrated Indian. She had to do this for four years, which means as part of the treatment she had very poor vision for those years.

For Malikaa it wasnt easy. But she carried on undeterred with only one thing in her mindto excel in her chosen field and become a world-class tennis player. Self-driven and self-motivated, she undergoes training with a determination that is beyond her age.

As a result, in 2017, she is ranked first in the U-14 All India Tennis Association (AITA) rankings for girls. Women entering and succeeding in the field of sports isn't the same as men because they have to break multiple barriers and fight a constant battle against social stigma.

Be it having to wear shorts or spend money on training, it isn't easy in a society where girl children are always seen as a burden and a liability. In a country like India, convincing a family to spend on a girl child is not even the most difficult partaccording to the Youth Ki Awaaz, the Indian government's attitude towards any sport other than cricket is abysmal. This is even more the case when it comes to sports that women are involved in.

We all remember the case ofDipa Karmakar, who nearly did not participate in the Olympic Games because of a lack of funding. In such a scenario, girls like Malikaaact as a constant source of hope for others to emulate.

Do you have an interesting story to share? Please write to us at tci@yourstory.com. To stay updated with more positive news, please connect with us onFacebookandTwitter.

See original here:
Meet Malikaa Marathe, the girl who went from having partial eyesight to becoming first in tennis - YourStory.com

Read More...

Women Face Higher Risk of Blindness Than Men – PR Newswire (press release)

April 24th, 2017 12:44 pm

Whatever the cause, there are a fewunique vision problems women need to watch out formore than men. Dry eye occurs at double the rate in postmenopausal women.3 In general, women are more susceptible to autoimmune diseases than men, many of which affect vision, such as lupus, Sjgren's syndrome and hyperthyroiditis. Also, pregnancy can cause vision changes due to the hormones pregnant women experience.

Good news is most vision loss is preventable. The Academy offers five simple steps to take control of your eye health today:

"Eye exams aren't only about checking a person's visual acuity or sharpness, but also determining the overall health of their eyes," said Rebecca J. Taylor, M.D., clinical spokesperson for the American Academy of Ophthalmology. "We encourage women as well as men to get regular eye care. By making vision a priority today, we can help protect our sight as we age."

To learn more ways to keep your eyes healthy, visit the American Academy of Ophthalmology'sEyeSmartwebsite.

About the American Academy of Ophthalmology The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart program provides the public with the most trusted information about eye health. For more information, visit aao.org.

1. National Eye Institute 2. National Eye Institute 3. Am J Ophthalmol.2003 Aug;136(2):318-26.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/women-face-higher-risk-of-blindness-than-men-300443529.html

SOURCE American Academy of Ophthalmology

http://www.aao.org

Read this article:
Women Face Higher Risk of Blindness Than Men - PR Newswire (press release)

Read More...

Eye safety in sports and recreation – Trinidad & Tobago Express

April 24th, 2017 12:44 pm

Eye injuries at sports and recreation can have serious consequences, even leading to loss of sight and an end to a promising career. Of the many sports and recreation-related eye injuries that occur each year, 90 per cent are preventable through use of appropriate protective eyewear. The risk of eye injury can vary depending on the activity. Make sure the level of eye protection you or others in your family use is appropriate for the type of activity. Regular eyeglasses and contact lenses do not offer proper eye protection from injury. If you wear spectacles, the lenses should be made of polycarbonate, an especially tough, non-shattering plastic material. Contact lenses offer no protection against injury and safety glasses or goggles must be used. High-risk sports

Sports-related eye injuries occur more frequently in cricket, basketball, squash, baseball and badminton. Injury may be sustained from equipment eg the ball or from a fellow players limbs or head. In cricket and baseball a helmet with a polycarbonate face mask or wire shield should be worn especially by the wicketkeeper and batsmen. This is very important for young inexperienced players eg under-16 cricketers and when facing up to fast bowlers. Boxing and full-contact martial arts pose an extremely high risk of serious and even blinding eye injuries. There is no satisfactory eye protection for boxing, although thumbless gloves may reduce the number of boxing eye injuries. Approved eye ware should be bought from professional eye care providers. Protective eyewear with polycarbonate lenses is recommended for sports such as basketball, racquet sports, soccer and hockey. Choose eye protectors that have been tested to meet the American Society of Testing and Materials (ASTM) standards or that pass the CSA racquet sports standard. If you already have reduced vision in one eye, consider the risks of injuring the stronger eye before participating in contact or racquet sports, which pose a higher risk of eye injury. Check with your ophthalmologist (Eye MD) to see if appropriate eye protection is available and whether or not participating in contact or racquet sports is advised. Other risky leisure activities

In 2008 a survey conducted by the American Academy of Ophthalmology and the American Society of Ocular Trauma showed that more than 40 per cent of patients treated for eye injuries sustained at home were involved in home repairs, yard work, cleaning and cooking. Use common sense and err on the side of caution, whatever the activity. Consider the risk of flying debris or other objects during activities and wear appropriate eye protection. Remember that eyeglasses arent sufficient protection. Be careful during activities or games involving projectiles and other sharp objects that could create injury if in contact with the eye, eg fishing. If you wear contacts or eyeglasses, pack a back-up form of vision correction during bike trips or other activities where you could lose or shatter a lens. If an eye injury occurs, see an ophthalmologist or go to the hospital emergency room immediately, even if the eye injury appears minor. Delaying medical attention can result in permanent vision loss or blindness.

DO NOT touch, rub or apply pressure to the eye. DO NOT try to remove any object stuck in the eye. For small debris, lift eyelid and ask child to blink rapidly to see if tears will flush out the particle. If not, close the eye and seek treatment. Do not apply ointment or medication to the eye. A cut or puncture wound should be gently covered. Only in the event of chemical exposure, flush with plenty of water. Source of information: The American Academy of Ophthalmology.

Presented as a public service by the Caribbean Eye Institute. Eye related questions can be sent to Caribeyett@icloud.com

See the rest here:
Eye safety in sports and recreation - Trinidad & Tobago Express

Read More...

Diabetes may cause more deaths than previously thought – The Messenger (subscription)

April 24th, 2017 12:43 pm

Four times as many deaths may be caused by diabetes, according to a recent study by Boston University School of Public Health published in the online journal PLOS One.

The study argued that diabetes caused 12 percent of deaths in the U.S. Currently, death certificates indicate that 3.3 percent of deaths in the U.S. are caused by diabetes. If the studys findings prove to be accurate, diabetes would become the third-leading cause of death in the United States, up from the seventh.

According to the Kentucky Behavioral Risk Factor Surveillance Survey, diagnosed diabetes among adults nearly doubled in Kentucky from 6.5 percent to 12.5 percent from 2000 to 2014. Now, one in eight Kentucky adults, or 424,670 people in Kentucky are estimated to have diagnosed diabetes.

In 2015, the rate of diabetes increased again to 13.4 percent. Nationally, nearly 10 percent of people have diabetes.

The Centers for Disease Control estimates 138,000 Kentuckians are living with undiagnosed diabetes.

The Pennyrile region of Kentucky has a comparatively average rate of diabetes, at 12.1 percent. Regions along the eastern part of Kentucky have rates as high as 17.8 percent.

It was surprising to me that they would put it at 3 percent, said Christian County Health Department Nurse Jennifer Boone. Diabetes is just so hard on the entire body. It effects the entire body. All the organ systems, everything.

Diabetes is a group of diseases in which high levels of blood sugar are found in the body for extended periods of time.

Type 1 Diabetes comes from the pancreas failing to produce enough insulin. Type 2 Diabetes is usually caused by obesity and inactivity, when the body does not respond to insulin properly. Type 2 Diabetes usually occurs in later stages in life and is considered a result of lifestyle choices.

Its a lifelong thing. A lot of people think that if they eat healthy, if they exercise, if they are able to come off their medication then they dont have diabetes, Boone said. Its not like its ever really cured. Its just managed well.

Diabetes can cause kidney failure. It can also cause blindness, as the blood vessels in the eye can become damaged by the high amount of blood sugar caused by diabetes.

Gums can also become infected and inflamed by diabetes.

Any open wounds take longer to heal with diabetes, leading to many festering sores for those who suffer from the disease.

Kentucky has the 12th highest mortality rate in America. Exercise and a good diet are considered to be good forms of diabetes prevention.

People with higher than average blood sugar levels are considered to have prediabetes. Those with that condition can prevent diabetes with exercise and a good diet.

The Christian County Health Department advocated for the expansion of the Hopkinsville Greenway System during the debate over H-CC WINS, because the organization believed that the system would promote walking in the community, which would lead to better health.

Read more here:
Diabetes may cause more deaths than previously thought - The Messenger (subscription)

Read More...

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal – Xconomy

April 24th, 2017 12:43 pm

Xconomy New York

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for products used in treating vascular conditions and cancer.

Under the deal announced Sunday, Franklin Lakes, NJ-based Becton Dickinson (NYSE: BD) will pay Bard (NYSE: BCR) shareholders approximately $222.93 in cash and 0.5077 shares of BD stock per Bard share. That represents $317 for each Bard share, a 25.2 percent premium over Bards closing stock price Friday. When the deal closes, shareholders of Murray Hill, NJ-based Bard will own approximately 15 percent of the combined company.

BDs $12.4 billion in revenue last year was split between its Medical Segment, which makes diabetes care products and devices used by clinicians to manage and administer medication, and its Life Sciences Segment that sells products for collecting and transporting diagnostic specimens. The company says that Bard will help it expand beyond diabetes into areas such as peripheral vascular disease, urology, hernia, and cancer.

Bard operates four business units: oncology, vascular, urology, and surgical specialties. Vascular products made up more than $1 billion of the companys $3.7 billion in 2016 revenue, edging out oncology as the companys largest business unit. BD says that bringing Bards vascular products, such as catheters and ports, together with its devices that prepare, dispense, and administer drugs will help the combined entity address a wider range of medication management needs. BD, which conducts its research and development work in Research Triangle Park, NC, also says that the two companies together can offer a more comprehensive lineup of products addressing surgical site infections and catheter-related blood stream infections.

Both companies generate most of their revenue from U.S. customers, but BD notes that Bards head start in international markets, with about 500 products already registered for sale overseas, was attractive.

The combined company will have a large and growing presence in emerging markets, including $1 billion in annual revenue in China, BD said in a prepared statement.

The medical device sector has experienced a flurry of activity in recent years. In 2015, Medtronic (NYSE: MDT) closed on its acquisition of Mansfield, MA-based Covidien for $49.9 billion in cash and stock. Later that year medical device giant Zimmer acquired its Warsaw, IN, neighbor Biomet in a $13.35 billion cash and stock deal that formed Zimmer Biomet (NYSE: ZBH).

BDs Bard deal comes two years after it closed its $12.2 billion acquisition of San Diego-based CareFusion. CareFusion brought to BD its lineup of devices used for administering and managing medication, which were integrated into the New Jersey companys medical division. With the Bard acquisition, BD plans to create a third business unit called BD Interventional. BD says that Tom Polen, who is executive vice president of the BD Medical Segment, will become president of BD, effective immediately. In his new role, Polen will oversee all three of BDs business segments.

The boards of directors of both BD and Bard have approved the deal. The companies expect the acquisition to close in the fall of this year.

Photo by Flickr user Tareq Salahuddinvia a Creative Commons license.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com

Read more from the original source:
Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal - Xconomy

Read More...

Russia Diabetes Market Report: 2017 – 2022 – Research and Markets – Yahoo Finance

April 24th, 2017 12:43 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Russia Diabetes Market Report: 2017 - 2022" report to their offering.

Russia Diabetes Market Report: 2017 - 2022 provides an analytical and statistical insight into the Russia diabetes market. The report provides both current and future trends in the prevalence, demo-graphical breakup, diagnosis and treatment of diabetes in Russia.

The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Russia diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Russia diabetes market in any form.

Scope of the Report:

Comprehensive situation analysis of the Russia diabetes epidemiology and its dynamics:

Comprehensive situation analysis of the Russian Oral Antidiabetics market and its dynamics:

Comprehensive situation analysis of the Russian Insulin market and its dynamics:

Key Topics Covered:

1 Preface

2 Research Methodology

3 Executive Summary

4 Introduction

5 Diabetes Disease Overview

6 Russia Diabetes Epidemiology

7 Russia Diabetes Market

For more information about this report visit http://www.researchandmarkets.com/research/633bdx/russia_diabetes

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005826/en/

The rest is here:
Russia Diabetes Market Report: 2017 - 2022 - Research and Markets - Yahoo Finance

Read More...

Reversing Gene Damage to Treat Blindness | Technology Networks – Technology Networks

April 24th, 2017 12:42 pm

Confocal micrograph of mouse retina depicting optic fiber layer. Image courtesy of National Center for Microscopy and Imaging Research, UC San Diego.

Using the gene-editing tool CRISPR/Cas9, researchers at University of California San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health, with colleagues in China, have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa.

The findings are published in the April 21 advance online issue of Cell Research.

Retinitis pigmentosa (RP) is a group of inherited vision disorders caused by numerous mutations in more than 60 genes. The mutations affect the eyes photoreceptors, specialized cells in the retina that sense and convert light images into electrical signals sent to the brain. There are two types: rod cells that function for night vision and peripheral vision, and cone cells that provide central vision (visual acuity) and discern color. The human retina typically contains 120 million rod cells and 6 million cone cells.

In RP, which affects approximately 100,000 Americans and 1 in 4,000 persons worldwide, rod-specific genetic mutations cause rod photoreceptor cells to dysfunction and degenerate over time. Initial symptoms are loss of peripheral and night vision, followed by diminished visual acuity and color perception as cone cells also begin to fail and die. There is no treatment for RP. The eventual result may be legal blindness.

In their published research, a team led by senior author Kang Zhang, MD, PhD, chief of ophthalmic genetics, founding director of the Institute for Genomic Medicine and co-director of biomaterials and tissue engineering at the Institute of Engineering in Medicine, both at UC San Diego School of Medicine, used CRISPR/Cas9 to deactivate a master switch gene called Nrl and a downstream transcription factor called Nr2e3.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, allows researchers to target specific stretches of genetic code and edit DNA at precise locations, modifying select gene functions. Deactivating either Nrl or Nr2e3 reprogrammed rod cells to become cone cells.

Cone cells are less vulnerable to the genetic mutations that cause RP, said Zhang. Our strategy was to use gene therapy to make the underlying mutations irrelevant, resulting in the preservation of tissue and vision.

The scientists tested their approach in two different mouse models of RP. In both cases, they found an abundance of reprogrammed cone cells and preserved cellular architecture in the retinas. Electroretinography testing of rod and cone receptors in live mice show improved function.

Zhang said a recent independent study led by Zhijian Wu, PhD, at National Eye Institute, part of the National Institutes of Health, also reached similar conclusions.

The researchers used adeno-associated virus (AAV) to perform the gene therapy, which they said should help advance their work to human clinical trials quicker. AAV is a common cold virus and has been used in many successful gene therapy treatments with a relatively good safely profile, said Zhang. Human clinical trials could be planned soon after completion of preclinical study. There is no treatment for RP so the need is great and pressing. In addition, our approach of reprogramming mutation-sensitive cells to mutation-resistant cells may have broader application to other human diseases, including cancer.

This article has been republished frommaterialsprovided by University of California - San Diego. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Zhu, J., Ming, C., Fu, X., Duan, Y., Hoang, D. A., Rutgard, J., . . . Zhang, K. (2017). Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors. Cell Research. doi:10.1038/cr.2017.57

See the original post:
Reversing Gene Damage to Treat Blindness | Technology Networks - Technology Networks

Read More...

Global Biotechnology Reagents Market to Grow at a CAGR of 10.13% by 2021 – Rising Demand for Ready-to-use … – Yahoo Finance

April 24th, 2017 12:41 pm

DUBLIN, Apr. 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Biotechnology Reagents Market 2017-2021" report to their offering.

Research and Markets Logo

The global biotechnology reagents market to grow at a CAGR of 10.13% during the period 2017-2021.

The report, Global Biotechnology Reagents Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Ready-to-use reagents help minimize calculation, dilution, and pipetting errors. They reduce the duration of the diagnostic procedure and prevent contamination of samples. These factors have resulted in the demand for ready-to-use reagents among clinical laboratories and hospitals.

According to the report, the biotechnology industry is spending a huge amount on R&D to innovate new techniques and technologies. The companies are more focused to improve the products, their quality, and standards. The biotech companies are majorly spending on protein synthesis, drug assessment, therapeutics, DNA and RNA analysis, and cell culture applications. Biotechnology reagents are used in all the processes.

Further, the report states that biotechnology instruments are often complex and require sophisticated software for various measurement procedures. To operate the instruments and analyze a sample, the user must have a significant level of training with not only the method and the instrument but also the software required to run the analysis and the collection of data.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by technology

PART 07: Market segmentation by application

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/dqbbgf/global

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biotechnology-reagents-market-to-grow-at-a-cagr-of-1013-by-2021---rising-demand-for-ready-to-use-reagents-among-clinical-laboratories--hospitals---research-and-markets-300443626.html

See more here:
Global Biotechnology Reagents Market to Grow at a CAGR of 10.13% by 2021 - Rising Demand for Ready-to-use ... - Yahoo Finance

Read More...

‘Thirsty plants’ to land conservation: How biotechnology helps address developing world’s agricultural challenges – Genetic Literacy Project

April 24th, 2017 12:41 pm

[Editors note:Sarah Evanega holds a doctorate in plant biology from Cornell University, where she is the director of the Alliance for Science and senior associate director for International Programs at the College of Agriculture and Life Sciences.]

Agriculture plays a critical role in food security, political stability, and world peace and yet it leaves a big environmental footprint.

Fortunately, scientific innovationsincluding agricultural biotechnologyare helping us meet these challenges.

The Land Conservation Problem

To feed a growing population without encroaching further onto wild lands, scientists are looking to produce more food on less land. Researchers are exploring such ingenious approaches as increasing the rates by which plants perform photosynthesis: the process of using light, water, and CO2 to produce biomass and food. Ultimately, this may help plants sequester CO2 more efficiently, which could boost yields without increasing cultivated acreage. These applications of genetic engineering are innovative models for helping us to produce more with less.

The Pesticide Problem

Researchers in Bangladesh helped reduce insecticide use by smallholder farmers when they developed a variety of insect-resistant eggplant or brinjal, as it is known in South Asia in 2014. Brinjal that incorporates resistance conferred by bacillus thuringiensis (Bt) required the will of forward-thinking political leaders, such as Bangladesh Agriculture Minister Matia Chowdhury, to get approved and on the market. Now, farmers who used to spray their brinjal as frequently as twice a day have reduced their pesticide use by as much as 80 percent.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Scientific innovations solving agricultural problems

For more background on the Genetic Literacy Project, read GLP on Wikipedia

See the original post:
'Thirsty plants' to land conservation: How biotechnology helps address developing world's agricultural challenges - Genetic Literacy Project

Read More...

NutriBullets SuperFood Boost Featuring Plandai Biotechnology’s … – Yahoo Finance

April 24th, 2017 12:41 pm

LONDON, UNITED KINGDOM--(Marketwired - Apr 24, 2017) - Planda Biotechnology, Inc. ( OTCQB : PLPL ) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost featuring Planda's Phytofare Catechin Complex will be available at retail outlets across the United States as early as May 2017.As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, will now be featuring Planda's Phytofare Catechin Complex as the active ingredient in their product, SuperFood Fat Burning Boost.Capital Brands is expected to launch the revised product containing Phytofare with their retailers and on their website (nutriliving.com) as early as next month.

Callum Cottrell-Duffield, Chief Operating Officer for Planda Biotechnology, commented, "We are excited to have Phytofare associated with such a fantastic brand as Nutribullet. Their use of Phytofare as an active ingredient in their reformulation is a clear indication of their commitment to use only the best ingredients to ensure that their customers receive a supremely effective product. It is also testimony to our shareholders that we are indeed on the right track and that our Phytofare ingredients are game changers for the supplement industry."

NutriBullet has formulated specialized, plant-based SuperFood products using a variety of plant proteins,prebiotic and other dietary fibers, proprietary spice blends, and other unique ingredients etc. that can be easily combined into healthy smoothies using their industry-leading nutrient extraction blenders. The company uses all GMO-free ingredients sourced from the world's most reputable farms that undergo extensive testing for purity, effectiveness and flavor.

Planda operates an 8,000-acre estate in Mpumalanga, South Africa, where it grows and processes the green tea used in its Phytofare products. The company uses solar power for on-site housing and organic, sustainable farming practices to ensure the highest quality. Between the farm and factory, the company provides employment for hundreds of local families and, through profit sharing and rental payments, is able to bring economic value to the Zulu community.

About Capital Brands LLC Capital Brands LLC and its subsidiaries create, produce, and sell NutriBullet blenders as well as SuperFood formula mixes and other accessories for their blenders that help give the consumer the best possible health benefits using only the best and most quality ingredients available. The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere. For more information, please visit https://www.nutribullet.com/."NutriBullet" and "SuperFood Fat Burning Boost" are the registered trademarks of Capbran Holdings, LLC.

About Planda Biotechnology, Inc. Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

More:
NutriBullets SuperFood Boost Featuring Plandai Biotechnology's ... - Yahoo Finance

Read More...

Puma Biotechnology (PBYI) Earns News Sentiment Rating of 0.44 – Transcript Daily

April 24th, 2017 12:41 pm

Post Analyst
Puma Biotechnology (PBYI) Earns News Sentiment Rating of 0.44
Transcript Daily
Puma Biotechnology logo Press coverage about Puma Biotechnology (NYSE:PBYI) has been trending positive on Monday, Alpha One reports. The research group, a unit of Accern, ranks the sentiment of media coverage by analyzing more than 20 million ...
Puma Biotechnology Inc Risk Points versus Health Care - CMLvizCML News
Hot Stocks Report: Puma Biotechnology, Inc. (NASDAQ:PBYI), Celldex Therapeutics, Inc. (NASDAQ:CLDX)Post Analyst
Puma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Hold" from BrokeragesSports Perspectives
BBNS -The Cerbat Gem -Petro Global News 24
all 18 news articles »

Continued here:
Puma Biotechnology (PBYI) Earns News Sentiment Rating of 0.44 - Transcript Daily

Read More...

Why so many biotechnology start-ups, like Theranos, fail | Genetic … – Genetic Literacy Project

April 24th, 2017 12:41 pm

Two years after the $9 billion start-up unicorn Theranos crumbled, Silicon Valley still appears to be struggling to learn its lesson when it comes to health and medical start-ups. Improbable-sounding companies continue to turn up with tens of millions of dollars in funding, no published research to back them up, and nothing but criticism from scientists.

Venture-capital firms insist that the standard that needs to be met for investment is much higher for medical start-ups, which must prove that their technology works with data, not just a pitch. And yet somehow, when these start-ups finally surface to public consciousness, they dont appear to pass even the most basic smell test with literally any experienced researcher in the field.

There is a pervasive sense in Silicon Valley, bolstered by ten years of world-conquering success, that any sufficiently intelligent, sufficiently driven person can will what they want.

But the move fast and break things mantra that has helped Silicon Valley disrupt countless industries over the last two decades is more dangerous when applied to medical scienceThe things being broken by health start-ups are laws of science and ironclad guidelines for research. When a health start-up moves fast and breaks things, it can directly result in the death, dismemberment, and injury of real people.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Why Silicon Valley Keeps Getting Biotechnology Wrong

For more background on the Genetic Literacy Project, read GLP on Wikipedia

The rest is here:
Why so many biotechnology start-ups, like Theranos, fail | Genetic ... - Genetic Literacy Project

Read More...

Athletics and strong will help Matamata teen battle rare arthritis – Stuff.co.nz

April 24th, 2017 12:41 pm

REXINE HAWES

Last updated16:36, April 24 2017

Rexine Hawes

Matamata student Ollie Morton-Farrelly hasn't let a rare health condition stop him from winning track and field medals and smashing records.

A young athlete is breaking records, despite a rare childhood form of arthritis.

Oliver (Ollie) Morton-Farrelly, a Year Nine Matamata College student was diagnosed with enthesitis arthritis.

But Ollie is a fiercely competitive and determined young man.

Supplied

Ollie Morton-Farrelly is breaking records in both discuss and shot put, despite battling childhood arthritis.

In the 2016-2017 athletic season, which was his first Ollie broke five records and won five medals, including two golds, two silver and bronze.

But it's been a rough road.

A downward spiral in his health threeyears ago brought the sporty young man to a standstill and literally to his knees.

Supplied

Ollie Morton-Farrelly competing in shot put.

Mum Helene Mortonsays Ollie's condition started as a tummy ache, which steadily grew into severe joint pains.

"He started hobbling, like an old man.

"The colder it got, the worse he got."

After weeks of missing school due to lethargy and sickness, his mum took him to the GP.

Over the course of a year, he was referred to WaiKids Paediatrics in Hamilton, and then on to Starship.

"We were frustrated," said Helene. "He was missing school and was tired all the time."

After numerous blood tests, x-rays and MRIs, a genetic test finally provided an answer.

Ollie has enthesitis arthritis, where the tendon hits the joint.

"It was a relief, when we knew what we were dealing with," she said.

Dad Derek has ankylosing spondylitis, spinal arthritis.

Ollie manages the condition with medicine, but it has hadan adverse effect on his gut.

He takes daily medication for the arthritis, pain relief and medicinesto protect his gut.

He has three monthly tests to check his liver and kidney function.

When the weather is warm, Ollie is on form, but life can go downhill fast once winter and sickness sets in.

"I can sleep most of the day," he said.

"It's not cool. I wish I was normal."

A meeting with coach Roy Williams at the Te Aroha Athletics Club, where his sister Emma trains, changed everything.

Williams is a former Commonwealth Games gold medallist in track and field decathlon.

He approached Ollie to ask why he wasn't participating in the athletics events.

After a detailed explanation, Williams took the young boy on.

"He thought it was really sad," said Ollie.

"He helped me with my technique in shot put.

"It was really cool someone cared and went out of their way to help me."

Over a year with Williams, shot putstarted putting pressure on Ollie's joints during winter training.

So, Ollie took on discusstoo.

The switch helped equalise the joint pressure.

Williams has helped Ollie's technique in shot put.

Rather than gliding, Ollie shuffles in the circle, which is less pressure on kneejoints.

Ollie works with Williams two days a week, however Helene says training is all dependant on Ollie's health.

Since the new year, Helene says Ollie has been achieving well with athletics.

He competed in the 100-metre relay the Waikato/BoP Relay champs in December.

He was fast and the coach wanted him in the final leg.

But afterwards, he was sore.

He hobbled to the tent, sat down and literally couldn't get back up.

With shot put to go, Helene strapped his knees, to help take the pressure off them while standing.

He placedfirst.

Since January, Ollie has broken record after record in the discuss.

He broke the Matamata College record held since 1970, with his throw of 37.26mand the Matamata Athletics record of 24m, with his throw of 37.43.

In the North Island Colgate Games, Ollie placed 2nd, making him 3rdin New Zealand for shot put, for 12-year-olds.

Ollies last event at Easter, in the interprovincials in Masterton with the Waikato/BoP team was his best effort this year.

Ollie placed 1st in shot put and 3rd in discuss, from 90 participants in his age group.

He also came 11th in the 100m, with the fastest time for the Waikato/BoP.

Helene says it's all attributed to Williams' training and her son's determination.

Ollie plans to continue training through winter, as he can, and come summer, will hopefully smash more records.

"It's limited what I can do but I take every opportunity to be active," he said.

-Stuff

See the article here:
Athletics and strong will help Matamata teen battle rare arthritis - Stuff.co.nz

Read More...

PAAG Showing Promise as Arthritis Pain Reliever for Horses … – TheHorse.com

April 24th, 2017 12:41 pm

TheHorse.com
PAAG Showing Promise as Arthritis Pain Reliever for Horses ...
TheHorse.com
Researchers believe polyacrylamide hydrogel (PAAG) could have a long-lasting cushioning effect on arthritic joints.

and more »

Go here to read the rest:
PAAG Showing Promise as Arthritis Pain Reliever for Horses ... - TheHorse.com

Read More...

Global Stem Cell Therapy Market Growth at CAGR of 36.52%, 2017 … – Yahoo Finance

April 24th, 2017 12:40 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global Stem Cell Therapy Market 2017-2021" report to their offering.

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the sales of stem cell therapy products/segments in the market.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

Further, the report states that one of the major factors hindering the growth of this market is stringent regulatory environment affecting the product approvals. Gaining regulatory approval is often difficult, unpredictable, and subjective. Stem cell therapy must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/ld455v/global_stem_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005786/en/

View post:
Global Stem Cell Therapy Market Growth at CAGR of 36.52%, 2017 ... - Yahoo Finance

Read More...

Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage – BU News Service

April 24th, 2017 12:40 pm

Skiing in Aspen, Sean Fair mistimed a landing and felt a shooting pain in his right knee as he crumpled into the snow. He had to slide down the steep slope on his left ski. The doctor revealed that Fairs agony originated from a quarter-sized hole in the cartilage of his knee.

For an active person like Fair, traditional surgery options, like a total knee replacement, restrict motion and are less than ideal. Advances in experimental cartilage repair stem cell treatments, however, now offer new opportunities for young patients to preserve mobility, that defining value of youth.

Fair played football, among other sports, in high school. He played tennis in college and continued to play until he had his ski incident at the age of 31.

All of a sudden, not being able to do anything, I felt 80, he said. All my friends would play tennis together but I would have to sit back and watch.

Sean Fair was diagnosed with OCD, or osteochondritis dissecans. This condition typically develops in teenagers but doesnt usually present symptoms until adulthood when the joint experiences some form of trauma. OCD lesions involve holes, cracks, or loose articular cartilage in a joint.

Fair met with Dr. Andreas Gomoll, an orthopedic surgeon at the Brigham and Womens Hospital in Boston. They discussed knee replacement surgery, microfracture surgery and the possibility of using healthy cartilage from a cadaver donor.

Knee replacement surgery for patients as young as Fair often results with low satisfaction. People who receive the standard metal and plastic knee replacement are functionally limited and face unexpected physical challenges when it comes to activities more intense than a walk. Microfracture surgery would be better, but Fairs injury was too large for that to be practical. Fair and Gomoll decided to wait for a cadaver donor. While waiting, however, Fair joined a clinical trial to test a new approach that would fill the gap in his cartilage with stem cells.

Stem cells can be thought of as undecided cells. Theyre mostly present in embryos and neonates, but they are also found in adults as well. Given the correct environment, and depending on the type of stem cell, they can become more specific cells, like muscle cells or cartilage-forming cells. In Fairs case, Gomoll used donated umbilical cord stem cells from healthy babies delivered in the US. Umbilical cord stem cells are useful because they are able to morph into cartilage-forming cells, they dont require the destruction of an embryo and they have immunosuppressive properties that wouldnt cause Fairs body to reject them.

Anatomical representation of the human knee.

The procedure looked simple. Gomoll made a vertical incision in Fairs kneecap, cutting through the skin and the yellow fat to expose the white cartilage. Gomoll used stainless steel tools to clamp open the incision, while he used a metal ring spanner to scrape the edges of the cartilage pothole. (Picture using a spoon to carve a hole in a large eraser.) Next, the surgeon drilled seven coffee stirrer-sized holes into the bone at the bottom of the quarter-sized pothole. He injected the clear stem cell gel into each coffee stirrer-sized hole and then filled the quarter-sized hole up to its edges with the rest of the stem cell gel. Gomoll smoothed down the stem cell gel like icing on a cake. Then he sutured the wound closed.

Fair wasnt quick to start walking right after the procedure. His knee needed to heal and then he would have to follow a strict rehabilitation process of weekly physical therapy sessions.

Months after his surgery, the stem cells in Fairs knee developed into chondrocytes, cells that secrete a matrix of cartilage, and sealed the pothole in Fairs knee. As of now, Fair is thankful for his treatment. His right knee has healed, but hes still not at 100 percent.

My other knee unfortunately, because of all the issues the [right knee] had, also needs reconstruction, Fair said. Ive got to be careful when I carry my two-and-half-yearold down the steps. Functionally I can walk. I can chase him. I can outrun him, still. Other than that, its not a lot of peripheral movement I can do yet.

According to Gomoll, about 15 other Americans have received the same experimental treatment as Fair. Before this therapy can be offered at any hospital in the US, the clinical trial must obtain FDA approval after proving its efficacy with a larger, more randomized sample of patients. But Gomoll doesnt seem too worried. He says hundreds of patients in South Korea have already undergone the same procedure. Getting there will take some time and money; running comprehensive trials is expensive. Once the procedure is approved, Gomoll imagines thousands of cartilage damaged patients like Fair would potentially be treated with stem cells in the United States.

Go here to read the rest:
Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage - BU News Service

Read More...

Eye examination – Wikipedia

April 23rd, 2017 11:47 pm

An eye examination is a series of tests performed by an ophthalmologist (medical doctor), optometrist, or orthoptist assessing vision and ability to focus on and discern objects, as well as other tests and examinations pertaining to the eyes. Health care professionals often recommend that all people should have periodic and thorough eye examinations as part of routine primary care, especially since many eye diseases are asymptomatic.

Eye examinations may detect potentially treatable blinding eye diseases, ocular manifestations of systemic disease, or signs of tumours or other anomalies of the brain.

Ideally, the eye examination consists of an external examination, followed by specific tests for visual acuity, pupil function, extraocular muscle motility, visual fields, intraocular pressure and ophthalmoscopy through a dilated pupil.

A minimal eye examination consists of tests for visual acuity, pupil function, and extraocular muscle motility, as well as direct ophthalmoscopy through an undilated pupil.

Visual acuity is the eye's ability to detect fine details and is the quantitative measure of the eye's ability to see an in-focus image at a certain distance. The standard definition of normal visual acuity (20/20 or 6/6 vision) is the ability to resolve a spatial pattern separated by a visual angle of one minute of arc. The terms 20/20 and 6/6 are derived from standardized sized objects that can be seen by a "person of normal vision" at the specified distance. For example, if one can see at a distance of 20ft an object that normally can be seen at 20ft, then one has 20/20 vision. If one can see at 20ft what a normal person can see at 40ft, then one has 20/40 vision. Put another way, suppose you have trouble seeing objects at a distance and you can only see out to 20ft what a person with normal vision can see out to 200 feet, then you have 20/200 vision. The 6/6 terminology is more commonly used in Europe and Australia, and represents the distance in metres.

This is often measured with a Snellen chart or with a logMAR base Velorum Visual Acuity System.

In physics, "refraction" is the mechanism that bends the path of light through the eye. Refractive error is an optical abnormality in which the shape of the eye fails to bring light into sharp focus on the retina, resulting in blurred or distorted vision. Examples of refractive error are myopia, hyperopia, and astigmatism. In optometry, a "refraction" procedure is the measurement of refractive error by an eye care professional, usually for the purpose of correcting the error with glasses, contact lenses, or refractive surgery. A refraction procedure consists of two parts: objective and subjective.

An objective refraction is a refraction obtained without receiving any feedback from the patient, using a retinoscope or auto-refractor.

To perform a retinoscopy, the doctor projects a streak of light into a pupil. A series of lenses are flashed in front of the eye. By looking through the retinoscope, the doctor can study the light reflex of the pupil. Based on the movement and orientation of this retinal reflection, the refractive state of the eye is measured.

An auto-refractor is a computerized instrument that shines light into an eye. The light travels through the front of the eye, to the back and then forward through the front again. The information bounced back to the instrument gives an objective measurement of refractive error without asking the patients any questions.

A subjective refraction requires responses from the patient. Typically, the patient will sit behind a phoropter or wear a trial frame and look at an eye chart. The eye care professional will change lenses and other settings while asking the patient for feedback on which set of lenses give the best vision.

Researchers at the MIT Media Laboratory have proposed an eyepiece and software for use with a smartphone as a cheaper alternative to traditional subjective refraction equipment. The system is called NETRA ("near-eye tool for refractive assessment"). A patent was filed for the system in 2010, and the primary audience for the device was projected to be the developing world where access to eye care professionals is limited. The system uses an array of tiny lenses and a grid of pinholes that require the observer to visualize depth in what is otherwise a 2-dimensional surface (the smartphone screen). Rather than determining which of two images looks clearer, patients need only line up an array of dots and lines until they overlap. The degree of adjustment the patent uses on the handheld optical device to accomplish these tasks becomes a measure of visual acuity which can then be translated into an eyeglass prescription. The binocular auto-refractor measures sphere, cylinder, axis and pupillary distance. EyeNetra, the company marketing the devices, expects to bring them to market in February 2016 at a price of just over US$1,000 per device.[1]

Sometimes, eye care professionals prefer to obtain a cycloplegic refraction, especially when trying to obtain an accurate refraction in young children who may skew refraction measurements by adjusting their eyes with accommodation. Cycloplegic eye drops are applied to the eye to temporarily paralyze the ciliary muscle of the eye.

An examination of pupilary function includes inspecting the pupils for equal size (1mm or less of difference may be normal), regular shape, reactivity to light, and direct and consensual accommodation. These steps can be easily remembered with the mnemonic PERRLA (D+C): Pupils Equal and Round; Reactive to Light and Accommodation (Direct and Consensual).

A swinging-flashlight test may also be desirable if neurologic damage is suspected. The swinging-flashlight test is the most useful clinical test available to a general physician for the assessment of optic nerve anomalies. This test detects the afferent pupil defect, also referred to as the Marcus Gunn pupil. It is conducted in a semidarkened room. In a normal reaction to the swinging-flashlight test, both pupils constrict when one is exposed to light. As the light is being moved from one eye to another, both eyes begin to dilate, but constrict again when light has reached the other eye.

If there is an efferent defect in the left eye, the left pupil will remain dilated regardless of where the light is shining, while the right pupil will respond normally. If there is an afferent defect in the left eye, both pupils will dilate when the light is shining on the left eye, but both will constrict when it is shining on the right eye. This is because the left eye will not respond to external stimulus (afferent pathway), but can still receive neural signals from the brain (efferent pathway) to constrict.

If there is a unilateral small pupil with normal reactivity to light, it is unlikely that a neuropathy is present. However, if accompanied by ptosis of the upper eyelid, this may indicate Horner's syndrome.

If there is a small, irregular pupil that constricts poorly to light, but normally to accommodation, this is an Argyll Robertson pupil.

Ocular motility should always be tested, especially when patients complain of double vision or physicians suspect neurologic disease. First, the doctor should visually assess the eyes for deviations that could result from strabismus, extraocular muscle dysfunction, or palsy of the cranial nerves innervating the extraocular muscles. Saccades are assessed by having the patient move his or her eye quickly to a target at the far right, left, top and bottom. This tests for saccadic dysfunction whereupon poor ability of the eyes to "jump" from one place to another may impinge on reading ability and other skills, whereby the eyes are required to fixate and follow a desired object.

The patient is asked to follow a target with both eyes as it is moved in each of the nine cardinal directions of gaze. The examiner notes the speed, smoothness, range and symmetry of movements and observes for unsteadiness of fixation. These nine fields of gaze test the extraocular muscles: inferior, superior, lateral and medial rectus muscles, as well as the superior and inferior oblique muscles.

Testing the visual fields consists of confrontation field testing in which each eye is tested separately to assess the extent of the peripheral field.

To perform the test, the individual occludes one eye while fixated on the examiner's eye with the non-occluded eye. The patient is then asked to count the number of fingers that are briefly flashed in each of the four quadrants. This method is preferred to the wiggly finger test that was historically used because it represents a rapid and efficient way of answering the same question: is the peripheral visual field affected?

Common problems of the visual field include scotoma (area of reduced vision), hemianopia (half of visual field lost), homonymous hemianopsia and bitemporal hemianopia.

External examination of eyes consists of inspection of the eyelids, surrounding tissues and palpebral fissure. Palpation of the orbital rim may also be desirable, depending on the presenting signs and symptoms. The conjunctiva and sclera can be inspected by having the individual look up, and shining a light while retracting the upper or lower eyelid. The position of the eyelids are checked for abnormalities such as ptosis which is an asymmetry between eyelid positions.

Close inspection of the anterior eye structures and ocular adnexa are often done with a slit lamp which is a table mounted microscope with a special adjustable illumination source attached. A small beam of light that can be varied in width, height, incident angle, orientation and colour, is passed over the eye. Often, this light beam is narrowed into a vertical "slit", during slit-lamp examination. The examiner views the illuminated ocular structures, through an optical system that magnifies the image of the eye and the patient is seated while being examined, and the head stabilized by an adjustable chin rest.

This allows inspection of all the ocular media, from cornea to vitreous, plus magnified view of eyelids, and other external ocular related structures. Fluorescein staining before slit lamp examination may reveal corneal abrasions or herpes simplex infection.

The binocular slit-lamp examination provides stereoscopic magnified view of the eye structures in striking detail, enabling exact anatomical diagnoses to be made for a variety of eye conditions.

Also ophthalmoscopy and gonioscopy examinations can also be performed through the slit lamp when combined with special lenses. These lenses include the Goldmann 3-mirror lens, gonioscopy single-mirror/ Zeiss 4-mirror lens for (ocular) anterior chamber angle structures and +90D lens, +78D lens, +66D lens & Hruby (-56D) lens, the examination of retinal structures is accomplished.

Intraocular pressure (IOP) can be measured by Tonometry devices. The eye can be thought of as an enclosed compartment through which there is a constant circulation of fluid that maintains its shape and internal pressure. Tonometry is a method of measuring this pressure using various instruments. The normal range is 10-21 mmHg.

Examination of retina (fundus examination) is an important part of the general eye examination. Dilating the pupil using special eye drops greatly enhances the view and permits an extensive examination of peripheral retina. A limited view can be obtained through an undilated pupil, in which case best results are obtained with the room darkened and the patient looking towards the far corner. The appearance of the optic disc and retinal vasculature are also recorded during fundus examination.

A red reflex can be seen when looking at a patient's pupil through a direct ophthalmoscope. This part of the examination is done from a distance of about 50cm and is usually symmetrical between the two eyes. An opacity may indicate a cataract.

Children should have their first eye exam at 6 months old. If a parent suspects something is wrong an ophthalmologist can check even earlier.

Early eye exams are important because children need the following basic visual skills for learning:

Because of the importance of eye exams before students begin school, the Ontario Association of Optometrists started the Eye See...Eye Learn program in Ontario after it was successfully launched in Alberta in 2003. The program provides OHIP insured eye exams and free eyeglasses to Junior Kindergarten children in participating regions. Currently the program is being offered in the following regions for the 2010/2011 year: Halton, Hamilton-Wentworth, Peel and Windsor-Essex.

More here:
Eye examination - Wikipedia

Read More...

WATCH: A race to the US to save a newborn’s eyesight – STAT

April 23rd, 2017 11:47 pm

N

EW YORK How could we remove the eyeballs of a newborn baby? Feifei Lin said of her daughter, Lulu.

When she was just 47 days old, Lulu was diagnosed with retinoblastoma, a rare pediatric cancer that begins in the back of the eye. A doctor in Wenzhou, China, where the family was living at the time, detected tumors in both of Lulus eyes, and scheduled eye removal surgery for that afternoon.

The news left Lin devastated but also defiant.

advertisement

My husband and I both lost our vision when we were very young, she said. Having gone through this, we have to grasp her ever-so-little remaining vision.

Lulus cancer is hereditary. Her father, Yi Tang, also suffered from retinoblastoma when he was young, and his eyes were removed.

Lin and her husband were determined to do what they could to avoid a similar procedure.

In need of complex care, a Syrian child gets a second chance at a US hospital

On average, every year there are about 325 cases of retinoblastoma in the US, while about 2,000 children in China are diagnosed with it. In China, however, it is difficult to access cutting-edge treatment, and many children die of the cancer.

Worldwide, 70 percent of children with retinoblastoma die of the disease, but in the US, only 2 percent do, said Dr. Paul T. Finger, director of the Ocular Tumor Service at the New York Eye and Ear Infirmary of Mount Sinai.

Whats the difference? Finger said. The difference is early diagnosis and treatments.

Lulus parents saw their last, best hope in America.

Children with retinoblastoma often undergo a procedure known as intra-arterial chemotherapy. A thin catheter is inserted into a large artery on top of the leg and slowly threaded all the way up into the ophthalmic artery. Then the chemo is perfused just into the eye.

It was this method of treatment that brought Lulus family to Memorial Sloan Kettering Cancer Center in New York and also brought them hope.

Chinese families are increasingly coming to the US for the procedure, but costs are high. Lulus family managed to raise $160,000 for the initial treatment.

I know some families, they sold their home, they sold their car; all their relatives donated for them. Their friends donated for them, said Ying Song, who launched RB Childrens Foundation, a nonprofit established by the Chinese American Association of Metropolitan New York to help support these families financially.

Meanwhile, Fingers Eye Cancer Foundation is training doctors and setting up retinoblastoma centers in underserved countries around the world, including China, so that all patients can get access to treatments.

Although Luluhas lost much of her eyesight, her parents are hopeful that she can live a productive life. And they aredoing whatever it takes to ensure she can continue hertreatment in America.

Lulus eyes are so fragile and her vision has deteriorated so much, her mother said. We cant afford taking any more risks.

Fan Bu can be reached at fan.bu53@gmail.com Follow Fan on Twitter @fanbu_nyc

Melody Cao can be reached at iamcxl@gmail.com

See original here:
WATCH: A race to the US to save a newborn's eyesight - STAT

Read More...

Radiation therapy restores vision of three-year-old with eye cancer – The Indian Express

April 23rd, 2017 11:47 pm

The Indian Express
Radiation therapy restores vision of three-year-old with eye cancer
The Indian Express
The boy was not responding to chemotherapy, putting him at risk of losing his vision. However, doctors at AIIMS took a small disc, made from a radioactive element, and stitched it on to his eye, thereby saving his eyesight. The boy is the first patient ...

and more »

More:
Radiation therapy restores vision of three-year-old with eye cancer - The Indian Express

Read More...

Glaucoma may be causing you to lose your sight – Star2.com

April 23rd, 2017 11:47 pm

It was pitch black in the eatery when our motley media crew, in groups of eight, staggered in with hands on each others shoulders.

Our instructions were to follow our visually-impaired guide-cum-waiter, whod lead us to our table. The only sounds audible were the clinking of glasses and cutlery.

After taking a few cautious steps, one claustrophobic member asked to be escorted out as she was overcome with anxiety. I felt the hand on my shoulder grip harder.

Not a light, not a sight only nervous chatter as we sightlessly weaved our way to our seats at Dining In The Dark, a restaurant in total darkness.

We were about to have a sensory experience and enjoy a gastronomic journey, where food taste and flavours are not influenced by sight.

The food arrived in a few small plates placed on a bigger platter, with directions to pick up the plate and start eating, beginning clockwise, from the bottom left. It took some getting used to as the food kept slipping off the cutlery before reaching our mouths.

We tried to guess what we were eating, which was to be revealed upon the meals conclusion.

When dessert arrived in five little plates, I used my spoon to pick something that resembled a ball, but oops, it rolled off!

I imagined the terrible stains on my white blouse.

I tried using a folk to stab another dessert and it rolled off, too! Gosh, I was really leaving a mess on the floor. Two down, three to go.

This is what the blind have to deal with everyday.

Thin nerve fibre rim especially above and below. Note the plunging blood vessel as it enters the optic nerve. Photo: VISTA

Most of us take our sight for granted, and may not be aware that we may be losing our vision slowly, but surely.

The most common cause of blindness worldwide is cataracts, but a leading cause of irreversible blindness is glaucoma, with less than 50% of sufferers aware of their condition before blindness occurs.

Glaucoma is an eye disease where the optic nerve, which connects your eye to your brain, becomes progressively damaged.

It usually occurs when the fluid in the eye cannot drain properly, which increases the pressure inside the eye (intraocular pressure or IOL) and puts pressure on the optic nerve.

Glaucoma develops slowly and most patients do not feel their vision is affected for several years, says Assoc Prof Dr Jemaima. Photo: Novartis

If not treated, the disease would gradually worsen the peripheral visual field, leading to visual impairment and blindness. The optic nerve damage is permanent and irreversible, says consultant ophthalmologist Assoc Prof Dr Jemaima Che Hamzah, who was speaking at the launch of a combination eye-drop therapy here recently.

In Malaysia, glaucoma is the third leading cause of blindness after cataracts and diabetic retinopathy.

Its symptoms are subtle or even non-existent, thus many people are unaware they have the disease until they go for an eye check.

Left untreated, bit by bit, glaucoma robs their vision, and pretty soon, their world is plunged into darkness.

Assoc Prof Dr Jemaima says, Patients always present to us at the later stages.

Glaucoma develops slowly and most patients do not feel their vision is affected for several years.

This is because the loss of vision is at the periphery, while central vision remains stable until the disease is severe or the better eye is affected. By the time the patient is aware, it is already too late.

Sometimes, glaucoma can simulate the symptoms of a brain tumour, such as halos around light, sudden loss of vision, headache, severe eye pain, nausea and vomiting, so we send patients to the neurologist to rule this condition out.

The exact cause of glaucoma is unknown, but increased IOP is a recognised risk factor.

Other causes include age over 45 years, genetic history of glaucoma, diabetes, history of elevated IOP, decrease in corneal thickness and rigidity, high myopia, steroid use and previous eye trauma.

There are several types of glaucoma, but simply put, there is no cure, whether patients are seeking allopathic or homeopathic options. You cannot get your sight back; you can only slow down the disease progression.

As glaucoma becomes increasingly common with age, individuals over the age of 40, especially those at risk from risk factors are urged to schedule regular eye exams with their ophthalmologists. Or else, it can impact your quality of life with increased incidence of falls and motor accidents, says Assoc Prof Dr Jemaima.

The only treatment is to lower the IOL and prevent functional visual loss during the remainder of the patients life. This can be done via eye drops, laser treatment or surgery.

Treatment challenges

However, doctors face plenty of challenges in treating these patients, because once diagnosed, Assoc Prof Dr Jemaima says almost 80% of patients deviate from treatment, especially the elderly.

She adds, There is a high dropout rate due to many reasons inability to instil eye drops, forgetting to use the drops, poor knowledge of glaucoma, worsening visual field loss and lack of access to medication.

Adherence to therapy remains a key challenge among glaucoma patients, says Dr Teoh.

Consultant ophthalmologist and glaucoma specialist Datuk Dr Linda Teoh agrees that adherence to therapy remains a key challenge as patients have many drops to put in.

Back then, patients would cart around a big bag with multiple drugs wherever they went. But latest fixed combination drugs cut down on the number of times the drops are administered and lessen the side effects.

Unfortunately, you cannot put all the medications in at one go; you have to wait about five minutes between drops to give time for a drug not to be washed out. If youre a working adult, this takes time and is inconvenient, so this might affect adherence, says Dr Teoh.

The question everyone wants to know is how long before a glaucoma patient goes blind?

It depends on many factors and how motivated the patient is to comply with treatment, she says.

According to the United States-based Glaucoma Research Foundation, approximately 10% of people with glaucoma who receive proper treatment still experience loss of vision.

A 2014 study published by the American Academy Of Ophthalmology estimated that globally, 60 million individuals aged 40-80 had glaucoma in 2013; by 2020, this figure is anticipated to increase to 76 million, and by 2040, the numbers are expected to spike to a further 111 million.

This is going to pose a big burden as medications are very expensive. Vision lost to glaucoma cannot be restored, so its best detected early. Please get your eyes tested routinely, advises Dr Teoh.

Regular eye tests saved Sharon Ooi from losing her sight to glaucoma. Photo: Novartis

If she hadnt gone for an annual eye check-up a four years ago, Sharon Ooi Beng Poh could have easily lost her vision.

She was told her IOP was high and was referred to another specialist, who prescribed a battery of tests. Ooi had no other symptoms.

I had a sneaky feeling that something was not right, but the doctor didnt instil fear in me. Instead, she said our eye muscles will degenerate with age and asked if I would be afraid if she told me something. I said no, especially if there is a preventive measure. Then she diagnosed me as having glaucoma.

A former colleague had glaucoma and I recall her telling me she only had to put eye drops and all was well. The seriousness of the condition didnt really hit me until I listened to a talk, shares Ooi, who had a Lasik procedure done to correct her high myopia some years back.

Ooi was put on treatment immediately and with the availability of newer drugs, she now uses her eye drops twice a day at 7am and 7pm.

Life goes on as normal otherwise.

All comments are moderated. Your comment may not show up immediately. Please keep it clean and on topic. Offensive comments will not be published.

View original post here:
Glaucoma may be causing you to lose your sight - Star2.com

Read More...

Page 1,024«..1020..1,0231,0241,0251,026..1,0301,040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick